BRPI0008131B8 - composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno - Google Patents

composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno

Info

Publication number
BRPI0008131B8
BRPI0008131B8 BRPI0008131A BR0008131A BRPI0008131B8 BR PI0008131 B8 BRPI0008131 B8 BR PI0008131B8 BR PI0008131 A BRPI0008131 A BR PI0008131A BR 0008131 A BR0008131 A BR 0008131A BR PI0008131 B8 BRPI0008131 B8 BR PI0008131B8
Authority
BR
Brazil
Prior art keywords
group
carbon atoms
agent
oligonucleotide analog
salt
Prior art date
Application number
BRPI0008131A
Other languages
English (en)
Other versions
BR0008131A (pt
BRPI0008131B1 (pt
Inventor
Morita Koji
Kaneko Masakatsu
Imanishi Takeshi
Original Assignee
Daiichi Sankyo Co Ltd
Mitsubishi Kagaku Foods Corp
Sankyo Co
Sankyo Lifetech Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12398349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0008131(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd, Mitsubishi Kagaku Foods Corp, Sankyo Co, Sankyo Lifetech Company Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR0008131A publication Critical patent/BR0008131A/pt
Publication of BRPI0008131B1 publication Critical patent/BRPI0008131B1/pt
Publication of BRPI0008131B8 publication Critical patent/BRPI0008131B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene, iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno". [assunto] o objetivo da presente invenção é fornecer novos análogos de oligonucleotídeo, que exibam atividade anti-sentido ou antígena tendo excelente estabilidade, ou exibam excelente atividade como um agente de detecção (sonda) para um gene específico ou como um iniciador para começar a amplificação, e a novos análogos de nucleosídeo que sejam intermediários para a sua produção. [solução] um composto da fórmula (1): [em que r^ 1^ e r^ 2^ são os mesmos ou diferentes e representam um átomo de hidrogênio, um grupo de proteção de hidroxila, um grupo de ácido fosfórico, ou -p(r^ 3^)r^ 4^ [em que r^ 3^ e r^ 4^ são os mesmos ou diferentes e representam um grupo hidroxila, um grupo amino, um grupo alcóxi tendo de 1 a 4 átomos de carbono, um grupo cianoalcóxi tendo de 1 a 5 átomos de carbono ou um grupo amino substituído por um grupo alquila tendo de 1 a 4 átomos de carbono]; a representa um grupo alquileno tendo de 1 a 4 átomos de carbono; e b representa um grupo purin-9-ila, um grupo 2-oxo-pirimidin-1-ila ou um grupo purin-9-ila substituído ou um grupo 2-oxo-pirimidin-1-ila substituído tendo um substituinte selecionado do seguinte grupo <244>]; ou o sal deste; (grupo <244>) um grupo hidroxila que pode ser protegido, um grupo alcóxi tendo de 1 a 4 átomos de carbono, um grupo mercapto que pode ser protegido, um grupo alquiltio tendo de 1 a 4 átomos de carbono, um grupo alcóxi tendo de 1 a 4 átomos de carbono, um grupo amino que pode ser protegido, um grupo mono ou dialquilamino que pode ser substituído por um grupo alquila tendo de 1 a 4 átomos de carbono, um grupo alquila tendo de 1 a 4 átomos de carbono e um átomo de halogênio.
BRPI0008131A 1999-02-12 2000-02-10 composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno BRPI0008131B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3386399 1999-02-12
PCT/JP2000/000725 WO2000047599A1 (en) 1999-02-12 2000-02-10 Novel nucleosides and oligonucleotide analogues

Publications (3)

Publication Number Publication Date
BR0008131A BR0008131A (pt) 2002-04-09
BRPI0008131B1 BRPI0008131B1 (pt) 2016-12-27
BRPI0008131B8 true BRPI0008131B8 (pt) 2021-05-25

Family

ID=12398349

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0008131A BRPI0008131B8 (pt) 1999-02-12 2000-02-10 composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno

Country Status (26)

Country Link
US (4) US7335765B2 (pt)
EP (1) EP1152009B2 (pt)
JP (1) JP3420984B2 (pt)
KR (1) KR100573231B1 (pt)
CN (1) CN1273478C (pt)
AT (1) ATE287897T2 (pt)
AU (1) AU758956B2 (pt)
BR (1) BRPI0008131B8 (pt)
CA (1) CA2361318C (pt)
CZ (1) CZ296576B6 (pt)
DE (1) DE60017711T3 (pt)
DK (1) DK1152009T4 (pt)
ES (1) ES2234563T5 (pt)
HK (1) HK1040084B (pt)
HU (1) HU228398B1 (pt)
ID (1) ID30093A (pt)
IL (2) IL144338A0 (pt)
NO (1) NO320441B1 (pt)
NZ (1) NZ513402A (pt)
PL (1) PL208245B1 (pt)
PT (1) PT1152009E (pt)
RU (1) RU2233844C2 (pt)
TR (2) TR200604211T1 (pt)
TW (1) TW513438B (pt)
WO (1) WO2000047599A1 (pt)
ZA (1) ZA200106544B (pt)

Families Citing this family (484)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119184B2 (en) * 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
JP4148662B2 (ja) * 2000-08-10 2008-09-10 第一三共株式会社 ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
JP4151751B2 (ja) * 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
EP1334109B1 (en) 2000-10-04 2006-05-10 Santaris Pharma A/S Improved synthesis of purine locked nucleic acid analogues
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
WO2003033696A1 (en) * 2001-10-18 2003-04-24 Sankyo Company, Limited Vegf antisense compound
JP4383176B2 (ja) * 2002-02-13 2009-12-16 武 今西 ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2284269B1 (en) * 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
AU2013201763B2 (en) * 2002-11-18 2015-05-07 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
JP5132025B2 (ja) * 2002-11-19 2013-01-30 第一三共株式会社 新規２’，５’−オリゴアデニル酸類縁体
TWI347948B (en) 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions
EP2530155B1 (en) * 2002-11-25 2016-03-16 Masafumi Matsuo ENA nucleic acid drugs modifying splicing in mRNA precursor
CN1833034B (zh) 2003-06-20 2014-04-16 埃克斯魁恩公司 用于分析核酸混合物的探针、文库和试剂盒及其构建方法
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK1661905T3 (da) * 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
GB0324854D0 (en) * 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
DE602004015832D1 (de) 2003-11-07 2008-09-25 Daiichi Sankyo Co Ltd Verfahren zum nachweis von genetischem polymorphismus
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005116207A1 (ja) * 2004-05-28 2005-12-08 Sankyo Company, Limited テロメラーゼ阻害ｅｎａオリゴヌクレオチド
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
WO2006110314A2 (en) 2005-03-25 2006-10-19 Ambion, Inc. Methods and compositions for depleting abundant rna transcripts
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
US8883162B2 (en) * 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20090324587A1 (en) 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
CA2642657A1 (en) * 2005-12-09 2007-06-14 Riken Method for replicating nucleic acids and novel unnatural base pairs
CN103301475B (zh) * 2005-12-28 2016-08-03 斯克里普斯研究所 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
EP2505646A1 (en) * 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
EP2505647A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
EP2410053B2 (en) 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
EA200900741A1 (ru) * 2006-11-27 2010-04-30 Айзис Фармасьютикалз, Инк. Способы лечения гиперхолестеринемии
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008104978A2 (en) * 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009002944A1 (en) * 2007-06-22 2008-12-31 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CA2700953A1 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
CA2701845A1 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2009067647A1 (en) * 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
RU2010138558A (ru) * 2008-03-20 2012-03-27 Кварк Фармасьютикалс. Инк, (Us) Новые соединения миphk для ингибирования rtp801
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
WO2009144704A2 (en) * 2008-04-15 2009-12-03 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS FOR INHIBITING NRF2
CA2726052A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
US8431692B2 (en) 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
TWI455944B (zh) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
AU2009276763B2 (en) 2008-07-29 2015-07-16 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
CN107083386A (zh) * 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
MY188457A (en) * 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
CA2745329C (en) 2008-12-04 2022-07-12 Opko Curna, Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
US8592386B2 (en) 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
MX2011009751A (es) 2009-03-16 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
DE102009019476A1 (de) * 2009-05-04 2010-11-11 Biametrics Marken Und Rechte Gmbh Wiedererkennbarer Träger für optische Meßverfahren
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
EP2427554B1 (en) 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
EP2440214A4 (en) 2009-06-08 2013-07-31 Quark Pharmaceuticals Inc METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh) 2009-06-26 2016-11-09 库尔纳公司 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
KR101801407B1 (ko) 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US9044493B2 (en) 2009-08-11 2015-06-02 Curna, Inc. Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
CN102482670B (zh) 2009-08-21 2018-06-15 库尔纳公司 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
NO2480669T3 (pt) 2009-09-25 2018-04-07
US20120220649A1 (en) 2009-10-30 2012-08-30 Daiichi Sankyo Company, Limited Modified double-stranded polynucleotide
US20110110860A1 (en) 2009-11-02 2011-05-12 The Board Of Regents Of The University Of Texas System Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
CA2781896C (en) 2009-12-09 2021-03-30 Nitto Denko Corporation Modulation of hsp47 expression
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
CA2782366A1 (en) 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
ES2585829T3 (es) 2009-12-29 2016-10-10 Curna, Inc. Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
CA2785727C (en) 2009-12-31 2020-01-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
RU2612161C2 (ru) 2010-01-06 2017-03-02 Курна, Инк. Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
NO2524039T3 (pt) 2010-01-11 2018-04-28
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
ES2671877T3 (es) 2010-01-25 2018-06-11 Curna, Inc. Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
KR20130008560A (ko) 2010-03-12 2013-01-22 다이이찌 산쿄 가부시키가이샤 마이크로 ｒｎａ를 이용한 심근 세포의 증식 방법
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
CA2794189C (en) 2010-03-24 2022-01-11 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
CN102869777B (zh) 2010-04-02 2018-11-02 库尔纳公司 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
RU2693462C2 (ru) 2010-05-03 2019-07-03 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
CN109112126B (zh) 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
EP2412724A1 (en) 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CN103180445B (zh) 2010-10-22 2018-02-16 库尔纳公司 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
TW201307376A (zh) 2010-12-02 2013-02-16 Daiichi Sankyo Co Ltd 經修飾之單股多核苷酸
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
WO2012170771A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
MX340053B (es) 2011-06-15 2016-06-22 Grifols Therapeutics Inc * Metodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih).
US20140303235A1 (en) 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
KR101991980B1 (ko) 2011-09-06 2019-06-21 큐알엔에이, 인크. 소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
EP2773758B1 (en) 2011-11-03 2017-06-07 Quark Pharmaceuticals, Inc. Compositions for use in neuroprotection
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
ES2694592T3 (es) 2012-03-15 2018-12-21 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP3336189A1 (en) 2012-04-20 2018-06-20 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
JP2015523854A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
CN104583398A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节基因表达的组合物和方法
CN104583402A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP2013256452A (ja) * 2012-06-11 2013-12-26 Kawaken Fine Chem Co Ltd メラニン産生抑制剤とその組成物
ES2798301T3 (es) * 2012-06-18 2020-12-10 Daiichi Sankyo Co Ltd Intermedio para producción de análogos de nucleósidos, y procedimiento para su producción
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
EP2961853B1 (en) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014143158A1 (en) 2013-03-13 2014-09-18 The Broad Institute, Inc. Compositions and methods for labeling of agents
BR112015022156A2 (pt) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
US9822418B2 (en) 2013-04-22 2017-11-21 Icahn School Of Medicine At Mount Sinai Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
EP3052632A4 (en) 2013-10-04 2017-03-29 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
US9765332B2 (en) 2014-01-29 2017-09-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
HUE050704T2 (hu) 2014-04-01 2020-12-28 Biogen Ma Inc Összetételek a SOD-1 expressziójának modulálására
US9926556B2 (en) 2014-04-28 2018-03-27 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
CR20160554A (es) 2014-05-01 2017-03-07 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del factor b del complemento
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2016017422A1 (ja) * 2014-07-31 2016-02-04 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
IL234246A0 (en) 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US20170369872A1 (en) 2014-12-18 2017-12-28 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
CA3205381A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
KR20180043819A (ko) 2015-08-24 2018-04-30 로슈 이노베이션 센터 코펜하겐 에이/에스 Lna-g 방법
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
EP3371211B1 (en) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
HK1258434A1 (zh) 2015-11-12 2019-11-08 F. Hoffmann-La Roche Ag 来自灵长类物种的标准化神经元细胞测定试验
EP3389670A4 (en) 2015-12-04 2020-01-08 Ionis Pharmaceuticals, Inc. METHODS OF TREATING BREAST CANCER
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN116059236A (zh) 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
KR20250112919A (ko) 2015-12-21 2025-07-24 노파르티스 아게 타우 발현을 감소시키기 위한 조성물 및 방법
WO2023150553A1 (en) 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
CA3013683C (en) 2016-03-14 2021-07-13 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
CA3013799A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
EP3448881B1 (en) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
AU2017286811A1 (en) 2016-06-17 2018-11-22 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
AU2017285350A1 (en) 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
RU2019101298A (ru) 2016-07-01 2020-08-03 Ф. Хоффманн-Ля Рош Аг Антисмысловые олигонуклеотиды для модулирования экспрессии htra1
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
AU2017296195A1 (en) 2016-07-11 2019-01-24 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
AU2017326372B2 (en) 2016-09-14 2023-12-07 Janssen Biopharma, Inc. Modified oligonucleotides and methods of use
MD3519572T2 (ro) 2016-09-29 2024-03-31 Biogen Ma Inc Compuși și procedee de reducere a expresiei Tau
EP3518981A4 (en) 2016-10-03 2020-06-10 President and Fellows of Harvard College THERAPEUTIC RNA DELIVERY THROUGH ARRDC1 MICROVESICLES
WO2018087200A1 (en) 2016-11-11 2018-05-17 Roche Innovation Center Copenhagen A/S Therapeutic oligonucleotides capture and detection
US11033570B2 (en) 2016-12-02 2021-06-15 Cold Spring Harbor Laboratory Modulation of Lnc05 expression
KR20190100225A (ko) 2016-12-28 2019-08-28 다이이찌 산쿄 가부시키가이샤 알포트 증후군 치료약
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
US20190345496A1 (en) 2017-01-13 2019-11-14 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
WO2018130584A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
EP3568478A1 (en) 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rel expression
WO2018130581A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rela expression
EP3568479A1 (en) 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
US11180756B2 (en) 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
JP7048574B2 (ja) 2017-03-10 2022-04-05 国立研究開発法人国立成育医療研究センター アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
KR102684529B1 (ko) * 2017-03-10 2024-07-12 레이크우드 아메덱스, 인크. 항미생물 화합물, 조성물, 및 그의 용도
US11377468B2 (en) 2017-03-10 2022-07-05 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
JP7306653B2 (ja) 2017-03-17 2023-07-11 国立大学法人千葉大学 構造強化されたＳ－ＴｕＤを用いた新規がん治療法
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
WO2018212271A1 (ja) 2017-05-18 2018-11-22 国立大学法人京都大学 脊髄小脳変性症３６型の予防又は治療用組成物
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
US20200172903A1 (en) 2017-07-05 2020-06-04 Osaka University ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION
US11028390B2 (en) 2017-07-10 2021-06-08 Osaka University Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof
WO2019030313A2 (en) 2017-08-11 2019-02-14 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
CA3071033A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019038228A1 (en) 2017-08-22 2019-02-28 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
KR20260009385A (ko) 2017-08-25 2026-01-19 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
SG11202002149XA (en) 2017-09-14 2020-04-29 Janssen Biopharma Inc Galnac derivatives
CN111226114A (zh) 2017-10-13 2020-06-02 罗氏创新中心哥本哈根有限公司 用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
KR20200030594A (ko) 2017-10-16 2020-03-20 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
EP3697904A1 (en) 2017-10-17 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
WO2019111791A1 (ja) * 2017-12-07 2019-06-13 第一三共株式会社 ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
WO2019115416A2 (en) 2017-12-11 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en) 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
CA3085211A1 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Companion diagnostic for htra1 rna antagonists
US20200339982A1 (en) 2017-12-22 2020-10-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
CN111448316B (zh) 2017-12-22 2025-02-14 罗氏创新中心哥本哈根有限公司 新的硫代亚磷酰胺
CN111448317B (zh) 2017-12-22 2025-07-04 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
WO2019140102A1 (en) 2018-01-10 2019-07-18 Translate Bio Ma, Inc. Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
CN111699258A (zh) 2018-01-10 2020-09-22 哥本哈根罗氏创新中心 用于调控pias4表达的寡核苷酸
EP3737759A1 (en) 2018-01-12 2020-11-18 Roche Innovation Center Copenhagen A/S Alpha-synuclein antisense oligonucleotides and uses thereof
MY203356A (en) 2018-01-12 2024-06-25 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US20210095275A1 (en) 2018-01-12 2021-04-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating gsk3b expression
WO2019141656A1 (en) 2018-01-17 2019-07-25 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating erc1 expression
EP3740573A1 (en) 2018-01-18 2020-11-25 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
BR112020016170A2 (pt) 2018-02-09 2020-12-15 Genentech, Inc. Oligonucleotídeos terapêutico e antissenso, conjugado, sal farmaceuticamente aceitável, composição farmacêutica, método in vitro ou in vivo para modular a expressão de tmem106b, método para tratar ou prevenir uma doença, uso do oligonucleotídeo e uso ou método
WO2019165067A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
WO2019172286A1 (ja) 2018-03-09 2019-09-12 第一三共株式会社 糖原病Ｉａ型治療薬
SG11202008895WA (en) 2018-03-13 2020-10-29 Janssen Pharmaceutica Nv Modified oligonucleotides for use in treatment of tauopathies
MA52661A (fr) 2018-04-05 2021-02-17 Centre Leon Berard Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
JP2021522815A (ja) 2018-05-07 2021-09-02 ロシュ イノベーション センター コペンハーゲン エーエス 超並列シーケンシングを用いるｌｎａオリゴヌクレオチド治療法の品質管理法
CA3098623A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
US20210371860A1 (en) 2018-05-08 2021-12-02 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating myh7 expression
JP2021524450A (ja) 2018-05-18 2021-09-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ マイクロｒｎａ関連疾患の処置のための薬学的組成物
WO2019224172A1 (en) 2018-05-25 2019-11-28 Roche Innovation Center Copenhagen A/S Novel process for making allofuranose from glucofuranose
EP3802824A1 (en) 2018-06-05 2021-04-14 F. Hoffmann-La Roche AG Oligonucleotides for modulating atxn2 expression
CA3102236A1 (en) 2018-06-13 2019-12-19 Daiichi Sankyo Company, Limited Myocardial dysfunction therapeutic agent
CN112566640A (zh) 2018-06-18 2021-03-26 罗切斯特大学 治疗精神分裂症和其他神经精神病症的方法
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
WO2020007772A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
WO2020007702A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
WO2020007700A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting spi1
TWI862501B (zh) 2018-07-03 2024-11-21 瑞士商赫孚孟拉羅股份公司 用於調制 Tau 表現之寡核苷酸
EP3819378A4 (en) 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
WO2020007826A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mbtps1
WO2020007889A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting stat1
WO2020011743A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mafb
WO2020011653A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
WO2020011745A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
WO2020011744A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
CA3098267A1 (en) 2018-07-31 2020-02-06 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
BR112021001756A2 (pt) 2018-07-31 2021-05-11 Roche Innovation Center Copenhagen A/S oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3841220A1 (en) 2018-08-23 2021-06-30 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
WO2020038971A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting vcan
WO2020038973A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting sptlc1
WO2020038976A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting usp8
US20220160870A1 (en) 2018-08-28 2022-05-26 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
CA3114396A1 (en) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
CN112839662A (zh) 2018-10-17 2021-05-25 莱克伍德阿美达克斯股份有限公司 用于治疗口腔粘膜炎的方法和组合物
JP2022512877A (ja) 2018-11-01 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー Ｔｉａ１を標的とするアンチセンスオリゴヌクレオチド
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
MX2021005758A (es) 2018-11-15 2021-09-21 Ionis Pharmaceuticals Inc Moduladores de la expresión de irf5.
WO2020104492A1 (en) 2018-11-22 2020-05-28 Roche Innovation Center Copenhagen A/S Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020109344A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides
AU2019396450B2 (en) 2018-12-11 2025-08-28 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
JP2022514648A (ja) 2018-12-21 2022-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃａｒｄ９を標的とするアンチセンスオリゴヌクレオチド
CN113365607A (zh) 2019-01-25 2021-09-07 豪夫迈·罗氏有限公司 用于口服药物递送的脂质囊泡
TW202214854A (zh) * 2019-01-31 2022-04-16 美商Ionis製藥公司 Yap1表現之調節劑
EP3923962A2 (en) 2019-02-13 2021-12-22 University of Rochester Gene networks that mediate remyelination of the human brain
MX2021009950A (es) 2019-02-20 2021-09-21 Roche Innovation Ct Copenhagen As Oligonucleotidos gapmeros de fosfonoacetato.
WO2020169696A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Novel phosphoramidites
JP7503072B2 (ja) 2019-02-26 2024-06-19 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドの製剤化方法
WO2020176771A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
WO2020178258A1 (en) 2019-03-05 2020-09-10 F. Hoffmann-La Roche Ag Intracellular targeting of molecules
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
JP7413362B2 (ja) 2019-03-29 2024-01-15 シスメックス株式会社 新規人工核酸、その製造方法及び用途
JP7725370B2 (ja) 2019-04-03 2025-08-19 ブリストル－マイヤーズ スクイブ カンパニー Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
WO2020201339A1 (en) 2019-04-04 2020-10-08 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
CN113661168A (zh) 2019-04-16 2021-11-16 罗氏创新中心哥本哈根有限公司 用于制备核苷酸p(v)单体的新方法
EP3962918A1 (en) 2019-04-30 2022-03-09 Roche Innovation Center Copenhagen A/S Novel process for preparing rhenium chelated mag3 oligonucleotides
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
WO2020236600A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2020245233A1 (en) 2019-06-06 2020-12-10 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
AU2020286462B2 (en) 2019-06-06 2026-07-02 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
CN113924308B (zh) * 2019-06-19 2024-09-13 雅玛山酱油株式会社 交联型核苷中间体的结晶及其制造方法以及交联型核苷亚磷酰胺的制造方法
EP3995153A4 (en) 2019-06-26 2023-11-22 KNC Laboratories Co., Ltd. Nucleic acid drug suppressing production of myostatin gene mrna
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
JP7627495B2 (ja) 2019-07-12 2025-02-06 学校法人東海大学 ＤＵＸ４ ｐｒｅ－ｍＲＮＡのスプライシングを変化させるアンチセンスオリゴヌクレオチド
WO2021011936A2 (en) 2019-07-18 2021-01-21 University Of Rochester Cell-type selective immunoprotection of cells
PL3956450T3 (pl) 2019-07-26 2025-12-22 Ionis Pharmaceuticals, Inc. Związki i sposoby modulowania gfap
EP4013878A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
EP4013872A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
CA3147365A1 (en) 2019-08-14 2021-02-18 Joanne LIM Extracellular vesicle-nlrp3 antagonist
CN120771302A (zh) 2019-08-14 2025-10-14 隆萨销售股份公司 与分子连接的细胞外囊泡及其用途
CN114729327A (zh) 2019-08-14 2022-07-08 科迪亚克生物科学公司 具有stat3反义寡核苷酸的细胞外囊泡
CN114729356A (zh) 2019-08-14 2022-07-08 科迪亚克生物科学公司 靶向stat6的细胞外囊泡-aso构建体
KR20220062517A (ko) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도
IL291251B2 (en) 2019-09-10 2026-06-01 Daiichi Sankyo Co Limited CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
EP4034088A4 (en) 2019-09-26 2023-10-11 President and Fellows of Harvard College Minimal arrestin domain containing protein 1 (arrdc1) constructs
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
EP4047005A4 (en) * 2019-10-18 2024-03-06 Daiichi Sankyo Company, Limited PROCESS FOR MANUFACTURING BICYCLIC PHOSPHORAMIDITE
US20240148891A1 (en) 2019-10-18 2024-05-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN111109591A (zh) 2019-10-25 2020-05-08 新疆红旗坡农业发展集团有限公司 肠道微生态高效重建型苹果酵素及加工技术
EP4055165A1 (en) 2019-11-06 2022-09-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021092371A2 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2021099394A1 (en) 2019-11-19 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antisense oligonucleotides and their use for the treatment of cancer
WO2021122910A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sbds inhibitors for treating hepatitis b virus infection
EP4058032A4 (en) 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
CN114867856A (zh) 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
WO2021122921A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of cops3 inhibitors for treating hepatitis b virus infection
JP2023506540A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
JP7634542B2 (ja) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
WO2021123086A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for inhibiting scn9a expression
EP4081639A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス，インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
WO2021158810A1 (en) 2020-02-05 2021-08-12 Bristol-Myers Squibb Company Oligonucleotides for splice modulation of camk2d
EP4110916A1 (en) 2020-02-28 2023-01-04 F. Hoffmann-La Roche AG Oligonucleotides for modulating cd73 exon 7 splicing
EP4119167A4 (en) 2020-03-11 2025-08-06 Biocomber Co Ltd SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR INDUCING FRAME SHIFT-1 AND COMPOSITION
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
US12649761B2 (en) 2020-03-31 2026-06-09 Janssen Biopharma, Inc. Synthesis of oligonucleotides and related compounds
CN115551519A (zh) 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
CN115698290A (zh) 2020-05-11 2023-02-03 基因泰克公司 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
CN115605592A (zh) 2020-05-11 2023-01-13 基因泰克公司（Us） 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
WO2021229036A1 (en) 2020-05-13 2021-11-18 F. Hoffmann-La Roche Ag Oligonucleotide agonists targeting progranulin
US20230193269A1 (en) 2020-05-22 2023-06-22 Boehringer Ingelheim International Gmbh Oligonucleotides for splice modulation of card9
EP4162047A1 (en) 2020-06-09 2023-04-12 Roche Innovation Center Copenhagen A/S Guanosine analogues for use in therapeutic polynucleotides
AR122731A1 (es) 2020-06-26 2022-10-05 Hoffmann La Roche Oligonucleótidos mejorados para modular la expresión de fubp1
KR20230050336A (ko) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 뇌전증을 치료하기 위한 방법과 조성물
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2022018155A1 (en) 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Lna oligonucleotides for splice modulation of stmn2
EP4185696A1 (en) 2020-07-23 2023-05-31 F. Hoffmann-La Roche AG Oligonucleotides targeting rna binding protein sites
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2022024833A1 (ja) 2020-07-28 2022-02-03 神戸天然物化学株式会社 アンギオテンシン変換酵素２遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
WO2022043531A1 (en) * 2020-08-28 2022-03-03 Janssen Sciences Ireland Unlimited Company 7'-substituted 2'-o-4'-c-ethylene-bridged nucleic acid (ena) monomers and uses thereof
EP4219517A4 (en) 2020-09-25 2024-09-25 Riken Genesis Co., Ltd. NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING THE SAME AND USE THEREOF
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2022117745A1 (en) 2020-12-03 2022-06-09 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
TW202237843A (zh) 2020-12-03 2022-10-01 瑞士商赫孚孟拉羅股份公司 靶向ａｔｘｎ３之反義寡核苷酸
KR20230117182A (ko) 2020-12-04 2023-08-07 다인 세라퓨틱스, 인크. 항체-올리고뉴클레오티드 복합체 및 그의 용도
EP4259642A1 (en) 2020-12-08 2023-10-18 F. Hoffmann-La Roche AG Novel synthesis of phosphorodithioate oligonucleotides
EP4263831A1 (en) 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Antisense oligonucleotides for targeting progranulin
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
US20240343746A1 (en) 2020-12-31 2024-10-17 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
AU2021414227A1 (en) 2020-12-31 2023-07-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20240336914A1 (en) 2020-12-31 2024-10-10 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
EP4294456A1 (en) 2021-02-17 2023-12-27 Lonza Sales AG Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
JP2024512236A (ja) 2021-02-17 2024-03-19 ロンザ セールス アーゲー 細胞外ベシクル－ｎｌｒｐ３アンタゴニスト
US20240229036A9 (en) 2021-02-26 2024-07-11 Knc Laboratories Co., Ltd. Nucleic acid medicine expressing splicing variant of myostatin
KR20240009393A (ko) 2021-03-31 2024-01-22 엔트라다 테라퓨틱스, 인크. 사이클릭 세포 침투 펩티드
CA3213989A1 (en) 2021-04-01 2022-10-06 Conlin O'NEIL Extracellular vesicle compositions
JP2024518476A (ja) 2021-05-10 2024-05-01 エントラーダ セラピューティクス，インコーポレイティド ｍＲＮＡスプライシングを調節するための組成物及び方法
IL308353A (en) 2021-05-10 2024-01-01 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapies
US20250051393A1 (en) 2021-05-10 2025-02-13 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
CA3222546A1 (en) 2021-06-08 2022-12-15 F. Hoffmann-La Roche Ag Oligonucleotide progranulin agonists
AU2022298774A1 (en) 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
IL309897A (en) 2021-07-21 2024-03-01 Alnylam Pharmaceuticals Inc Target gene IRNA compositions associated with a metabolic disorder and methods of using them
EP4388094A1 (en) 2021-08-16 2024-06-26 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2023026994A1 (ja) 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
EP4395829A1 (en) 2021-09-01 2024-07-10 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
CN118019848A (zh) 2021-09-29 2024-05-10 豪夫迈·罗氏有限公司 Rna编辑
EP4416284A1 (en) 2021-10-15 2024-08-21 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023078883A1 (en) 2021-11-03 2023-05-11 F. Hoffmann-La Roche Ag Oligonucleotides for modulating apolipoprotein e4 expression
AU2022384619A1 (en) 2021-11-11 2024-04-11 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
CN118434858A (zh) 2021-12-07 2024-08-02 豪夫迈·罗氏有限公司 靶向actl6b的反义寡核苷酸
EP4448763A1 (en) 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG Oligonucleotide gba agonists
CN119095603A (zh) 2021-12-17 2024-12-06 豪夫迈·罗氏有限公司 用于调节rtel1和fubp1的寡核苷酸的组合
JP2024547071A (ja) 2021-12-20 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
WO2023122762A1 (en) 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2023127857A1 (ja) 2021-12-27 2023-07-06 株式会社理研ジェネシス 新規人工核酸、その製造方法及び用途
WO2023141507A1 (en) 2022-01-20 2023-07-27 Genentech, Inc. Antisense oligonucleotides for modulating tmem106b expression
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
AR128558A1 (es) 2022-02-21 2024-05-22 Hoffmann La Roche Oligonucleótido antisentido
EP4495241A1 (en) 2022-03-16 2025-01-22 Daiichi Sankyo Company, Limited Chemically-modified oligonucleotide having rnai activity
IL315659A (en) 2022-03-16 2024-11-01 Daiichi Sankyo Co Ltd siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2025516554A (ja) 2022-05-10 2025-05-30 エフ． ホフマン－ラ ロシュ アーゲー Ｃｆｐ－ｅｌｋ１遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド
EP4522742A2 (en) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
PE20250394A1 (es) 2022-05-18 2025-02-11 Hoffmann La Roche Oligonucleotidos mejorados que actuan sobre sitios de proteina de union a arn
KR20250022763A (ko) 2022-06-10 2025-02-17 캠프4 테라퓨틱스 코포레이션 조절 rna를 표적으로 하는 안티센스 올리고뉴클레오타이드를 사용하여 프로그래뉼린 발현을 조절하는 방법
WO2023242324A1 (en) 2022-06-17 2023-12-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for targeting progranulin
EP4547683A2 (en) 2022-06-30 2025-05-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
US20260049309A1 (en) 2022-08-15 2026-02-19 Novo Nordisk A/S Regulation of activity of rnai molecules
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
EP4332221A1 (en) 2022-08-29 2024-03-06 Roche Innovation Center Copenhagen A/S Threose nucleic acid antisense oligonucleotides and methods thereof
JP2025529283A (ja) 2022-09-06 2025-09-04 エフ． ホフマン－ラ ロシュ アーゲー 眼への投与のための二本鎖ｒｎａ分子
JP2025532985A (ja) 2022-09-30 2025-10-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド 修飾二本鎖ｒｎａ剤
US20260166072A1 (en) 2022-11-04 2026-06-18 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
EP4627084A1 (en) 2022-12-01 2025-10-08 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2024126654A1 (en) 2022-12-14 2024-06-20 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting actl6b
WO2024146935A1 (en) 2023-01-06 2024-07-11 Institut National de la Santé et de la Recherche Médicale Intravenous administration of antisense oligonucleotides for the treatment of pain
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
IL322261A (en) 2023-02-09 2025-09-01 Alnylam Pharmaceuticals Inc Reverser molecules and methods of using them
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
JP2026514045A (ja) 2023-04-12 2026-05-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 二本鎖ｒｎａ剤の肝外デリバリー
CN121263524A (zh) 2023-05-04 2026-01-02 豪夫迈·罗氏有限公司 能够上调葡糖脑苷脂酶表达的寡核苷酸
WO2024233864A2 (en) 2023-05-10 2024-11-14 Dicerna Pharmaceuticals, Inc. Galnac-conjugated rnai oligonucleotides
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
KR20260026070A (ko) 2023-06-16 2026-02-25 에프. 호프만-라 로슈 아게 Jak1 발현 조절을 위한 이중 가닥 올리고뉴클레오티드
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
WO2025047679A1 (ja) 2023-08-25 2025-03-06 学校法人福岡大学 リン酸部修飾を導入した安定型標的編集ガイドｒｎａ
WO2025054459A1 (en) 2023-09-08 2025-03-13 Dicerna Pharmaceuticals, Inc. Rnai oligonucleotide conjugates
WO2025064660A2 (en) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
AR134762A1 (es) 2023-12-21 2026-04-01 Hoffmann La Roche Oligonucleótido antisentido
CN117510564B (zh) * 2024-01-08 2024-03-08 苏州诺维康生物科技有限公司 一种医药中间体N2-Ac-5'-O-DMT-2'-O-炔丙基鸟苷的合成方法
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025252669A1 (en) 2024-06-03 2025-12-11 Evotec International Gmbh Modified oligonucleotides for reducing atxn3 expression
WO2025255388A1 (en) 2024-06-05 2025-12-11 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2026041784A1 (en) 2024-08-23 2026-02-26 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
EP4711455A1 (en) 2024-09-11 2026-03-18 Aarhus Universitet Small artificial rna (smartrna) oligonucleotide for modulating protein expression
WO2026061986A1 (en) 2024-09-17 2026-03-26 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
EP4763209A1 (en) 2024-12-17 2026-06-24 Institut National de la Santé et de la Recherche Médicale Use of (alpha)s-setmar agonist for preventing or treating glioblastoma
WO2026132147A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting downstream of the transcripts 3' terminus
WO2026151811A1 (en) 2025-01-07 2026-07-16 Camp4 Therapeutics Corporation Compositions and methods for treating urea cycle disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
NZ209840A (en) 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5514788A (en) 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5591623A (en) 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
JPH06501843A (ja) 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザａ型ウイルス，アン・アーバｈ２ｎ２株の阻害
US6111094A (en) 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5442049A (en) 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5691461A (en) 1990-08-16 1997-11-25 Isis Pharmaceuticals, Inc. Oligonucleotides inhibiting candida germ tube formation
HUT63430A (en) 1990-08-16 1993-08-30 Isis Pharmaceuticals Inc Process for producing oligonucleotides influencing the effect of cytomegalovirus infection
JP2515230Y2 (ja) * 1990-08-31 1996-10-30 徹 松井 道糸通し糸付き浮子
RU2131436C1 (ru) * 1990-09-13 1999-06-10 Санофи Резистентные к нуклеазе олигонуклеозиды, способ их получения и резистентный к нуклеазе нуклеозидный димер
US5242906A (en) 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
WO1994008003A1 (en) 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5582986A (en) 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
EP0590082B1 (en) 1991-06-14 1999-10-27 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US5607923A (en) 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5681747A (en) 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
ES2153097T3 (es) 1995-04-07 2001-02-16 Mogens Havsteen Jakobsen Procedimiento de inmovilizacion fotoquimica de ligandos usando quinonas.
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
AU6425098A (en) * 1997-03-07 1998-09-22 Kvaerner Oilfield Products A.S Termination of a tension member, for use as a tendon for a tension leg platform
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US5955443A (en) 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
HK1049339B (en) 1999-09-10 2008-06-27 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
WO2005116207A1 (ja) 2004-05-28 2005-12-08 Sankyo Company, Limited テロメラーゼ阻害ｅｎａオリゴヌクレオチド

Also Published As

Publication number Publication date
US7816333B2 (en) 2010-10-19
AU758956B2 (en) 2003-04-03
US8957201B2 (en) 2015-02-17
BR0008131A (pt) 2002-04-09
EP1152009B2 (en) 2017-09-06
EP1152009B1 (en) 2005-01-26
BRPI0008131B1 (pt) 2016-12-27
ES2234563T5 (es) 2018-01-17
DE60017711T2 (de) 2005-11-17
DK1152009T3 (da) 2005-03-07
IL144338A0 (en) 2002-05-23
US20110009471A1 (en) 2011-01-13
NO20013899D0 (no) 2001-08-10
CZ296576B6 (cs) 2006-04-12
DE60017711T3 (de) 2018-01-11
DE60017711D1 (de) 2005-03-03
CN1273478C (zh) 2006-09-06
RU2233844C2 (ru) 2004-08-10
TR200604211T1 (tr) 2007-02-21
JP3420984B2 (ja) 2003-06-30
CZ20012574A3 (cs) 2002-02-13
ID30093A (id) 2001-11-01
ATE287897T2 (de) 2005-02-15
HUP0105367A2 (hu) 2002-05-29
US20090149404A1 (en) 2009-06-11
CA2361318A1 (en) 2000-08-17
AU2459800A (en) 2000-08-29
NZ513402A (en) 2003-06-30
PL208245B1 (pl) 2011-04-29
DK1152009T4 (en) 2017-12-11
WO2000047599A1 (en) 2000-08-17
TW513438B (en) 2002-12-11
HUP0105367A3 (en) 2005-10-28
TR200102328T2 (tr) 2002-01-21
ES2234563T3 (es) 2005-07-01
JP2000297097A (ja) 2000-10-24
KR20020013498A (ko) 2002-02-20
US20030207841A1 (en) 2003-11-06
IL144338A (en) 2013-11-28
US20020147332A1 (en) 2002-10-10
KR100573231B1 (ko) 2006-04-24
ZA200106544B (en) 2002-11-08
EP1152009A1 (en) 2001-11-07
CA2361318C (en) 2008-11-25
HU228398B1 (en) 2013-03-28
US7314923B2 (en) 2008-01-01
EP1152009A4 (en) 2002-06-05
HK1040084A1 (en) 2002-05-24
NO20013899L (no) 2001-10-10
US7335765B2 (en) 2008-02-26
HK1040084B (en) 2005-04-22
CN1347418A (zh) 2002-05-01
NO320441B1 (no) 2005-12-05
PT1152009E (pt) 2005-03-31

Similar Documents

Publication Publication Date Title
BR0008131A (pt) Composto ou um sal deste, análogo de oligonucleotìdeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotìdeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antìgeno
BR0012646A (pt) Composto, análogo de oligonucleotìdeo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um análogo de oligonucleotìdeo
BR9806413A (pt) Composto e uso do mesmo
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0211900A (pt) Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BRPI0512588A (pt) derivados de uréia de pirimidina como inibidores de cinase
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
BR0004786A (pt) Compostos farmaceuticamente ativos
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR0214177A (pt) Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
BRPI0621668B8 (pt) composição ácida para limpar superfícies de metal ou ligas que são suscetíveis à corrosão, solução de uso aquosa e método para limpar superfícies de metal que são suscetíveis à corrosão
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
IL121305A (en) Neuraminic acid derivatives and pharmaceutical compositions containing the same
RU2001124910A (ru) Новые нуклеозидные и олигонуклеотидные аналоги
AR011571A1 (es) Un derivado de naftaleno, su uso, una composicion farmaceutica que lo comprende y un procedimiento para su preparacion
BR0316431A (pt) Análogo de 2&#39;, 5&#39; -oligoadenilato, uso do mesmo, e, composição farmacêutica
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
BR9911423A (pt) Derivados do ácido hidroxâmico como inibidores da produção de cd23 humano e da liberação de tnf
BR0012457A (pt) Alcalóides de indolcarbazol de um actinomiceto marinho
BR9812671A (pt) Tetrahidrofurano fosfato- e hidróxi ésteres, como pró-medicamentos para o correspondente agente antifúgico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SANKYO COMPANY, LIMITED (JP) , SANKYO LIFETECH COM

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: SANKYO COMPANY, LIMITED

B25A Requested transfer of rights approved

Owner name: SANKYO LIFETECH COMPANY LIMITED (JP) , DAIICHI SAN

Free format text: TRANSFERIDO POR INCORPORACAO DE: SANKYO COMPANY, LIMITED

B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP) , MITSUBISHI-

Free format text: TRANSFERIDO DE: SANKYO LIFETECH COMPANY LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25G Requested change of headquarter approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP) , MITSUBISHI-

B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10/02/2020